Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

11    Sanofi    $11.8    down 3.3%
Global revenue: $43.8B (6th); up 3.3%

R&D spend: $6.7B (6th), up 11.7%; 15.3% of rev.

Top brands: Lantus ($2.3B); Eloxatin ($806M); Lovenox ($633M); Taxotere ($243M); Plavix ($196M)

Planned launches: Teriflunomide (MS), visamerin (VTE), Lemtrada (MS), lixisenatide (diab.)

Promotional spend: $477M (12th); 4.0% of rev.

Patent expirations: Plavix (2012), Multaq (2014), Actonel (2014)

The diabetes medication merchant said in February that it expects business to fall off between 12% and 15% this year, as it weathers the aftershocks of patent losses on Lovenox, Ambien CR, Taxotere and Plavix. But it hopes to add diabetes treatment lixisenatide, a GLP-1 agonist scheduled to be filed this year. The GLP-1 field is a crowded one; Sanofi could bump up against Amylin's newcomer, Bydureon. Despite the uncertainty, Sanford Bernstein analyst Tim Anderson praised the company, in part because its patent cliff levels off next year.

Back to first page

Page 11 of 21
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters